The San Clemente, Calif.-based company said it plans to float 1.2 million shares of its common stock at $2.05 per share. The offering also includes unregistered warrants to purchase an additional 1.2 million shares at approximately 13¢ per warrant, which the company said could bring in an additional $150,000.
Funds from the placement are slated to support continued commercialization, clinical and product development activities and for general corporate purposes, ReShape Lifesciences said.
The offering is expected to close on July 12, ReShape said. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering, according to a press release.
Last month, ReShape Lifesciences said it inked approximately $1.5 million in offering deals with a number of institutional investors.
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.